Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Hosp Pediatr ; 11(10): e248-e252, 2021 10.
Article in English | MEDLINE | ID: mdl-34548391

ABSTRACT

BACKGROUND AND OBJECTIVES: Bronchiolitis is a viral syndrome that occurs in children aged <2 years and is a common reason for admission to children's hospitals. The American Academy of Pediatrics bronchiolitis guideline discourages routine antibiotic therapy for bronchiolitis. Despite this, there is high use of antibiotics in this patient population. METHODS: We performed a retrospective chart review of all patients aged ≤2 years admitted to our tertiary care center with bronchiolitis during 2 subsequent respiratory seasons. Between the 2 seasons, we provided an intervention to our hospital medicine group, which included a didactic review of American Academy of Pediatrics bronchiolitis guideline followed by subsequent, ongoing reinforcement from antibiotic stewardship weekday rounds. RESULTS: We were able to achieve a 40% decrease in overall antibiotic use between the 2 study periods (25% vs 15%, P < .001). CONCLUSIONS: Provider education, along with focused antibiotic stewardship audits with real-time feedback, resulted in decreased use of antibiotics in patients admitted with bronchiolitis.


Subject(s)
Anti-Bacterial Agents , Bronchiolitis , Anti-Bacterial Agents/therapeutic use , Bronchiolitis/drug therapy , Child , Guideline Adherence , Humans , Infant , Practice Patterns, Physicians' , Retrospective Studies
2.
Pediatr Infect Dis J ; 40(3): e128-e131, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33315746

ABSTRACT

Coccidioidal meningitis remains difficult to treat. The newer triazole, isavuconazole, has demonstrated efficacy in invasive fungal disease with less side effects than other azoles. We describe a case of refractory pediatric coccidioidal meningitis with disease stabilization and improvement on isavuconazole after failing treatment with other antifungal agents.


Subject(s)
Antifungal Agents/therapeutic use , Coccidioides , Coccidioidomycosis/drug therapy , Meningitis, Fungal/drug therapy , Nitriles/therapeutic use , Pyridines/therapeutic use , Salvage Therapy , Triazoles/therapeutic use , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Child , Deoxycholic Acid/administration & dosage , Deoxycholic Acid/therapeutic use , Drug Combinations , Humans , Meningitis, Fungal/microbiology , Voriconazole/administration & dosage , Voriconazole/therapeutic use
3.
Pediatr Pulmonol ; 51(8): 858-62, 2016 08.
Article in English | MEDLINE | ID: mdl-26829719

ABSTRACT

INTRODUCTION: In contrast to adults, coccidioidomycosis is a rare disease in infants and the mechanisms of disease acquisition are not well described in infants. The purpose of this study was to describe the clinical presentation, treatment, and outcome of pulmonary coccidioidomycosis in infants in an endemic area. METHODS: We performed a retrospective observational study of all patients less than 12 months of age admitted to a tertiary free standing children's hospital from 2003-2012 diagnosed with coccidioidomycosis. RESULTS: Thirteen infants were hospitalized during the study period. The majority of the patients presented with upper and/or lower respiratory tract infection. The most common presenting symptoms included fever (77%), cough (61%), and respiratory distress (38%). Disseminated disease, included pericardial effusion, neck abscess, and lesions in the cerebellum, basal ganglia and left temporoparietal skull. Fluconazole was the initial, antifungal agent used. Amphotericin B was reserved for significant lung disease and disseminated cases. Failed response to fluconazole and amphotericin B were treated with a combination of voriconazole and caspofungin. Average length of treatment was 4 years. All patients survived to hospital discharge. The majority of the patients had resolution of chest radiograph and coccidiodal complement fixing antibody titers. DISCUSSION: Infant coccidioidomycosis has a non-specific presentation and can mimic common infant respiratory illnesses. In endemic areas, coccidioidomycosis should be considered in the differential diagnosis of infants with pulmonary symptoms unresponsive to conventional treatment. Pediatr Pulmonol. 2016;51:858-862. © 2016 Wiley Periodicals, Inc.


Subject(s)
Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Lung Diseases, Fungal/diagnosis , Lung Diseases, Fungal/drug therapy , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Caspofungin , Cough/microbiology , Diagnosis, Differential , Echinocandins/therapeutic use , Endemic Diseases , Female , Fever/microbiology , Fluconazole/therapeutic use , Humans , Infant , Lipopeptides/therapeutic use , Male , Retrospective Studies , Treatment Outcome , Voriconazole/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL